In JoVE (1)
Other Publications (1)
Articles by Angela Steinmann in JoVE
Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System Laurence E. Court1, Kelly Kisling1, Rachel McCarroll1, Lifei Zhang1, Jinzhong Yang1, Hannah Simonds2, Monique du Toit2, Chris Trauernicht2, Hester Burger3, Jeannette Parkes3, Mike Mejia4, Maureen Bojador4, Peter Balter1, Daniela Branco1, Angela Steinmann1, Garrett Baltz1, Skylar Gay1, Brian Anderson1, Carlos Cardenas1, Anuja Jhingran5, Simona Shaitelman5, Oliver Bogler6, Kathleen Schmeller7, David Followill1, Rebecca Howell1, Christopher Nelson1, Christine Peterson8, Beth Beadle5,9 1Department of Radiation Physics, University of Texas MD Anderson Cancer Center, 2Department of Radiation Oncology, Stellenbosch University and Tygerberg Hospital, 3Departments of Radiation Oncology and Medical Physics, Groote Schuur Hospital and University of Cape Town, 4Department of Radiation Oncology, University of Santo Tomas Hospital, Benavides Cancer Institute, 5Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, 6Academic Affairs, University of Texas MD Anderson Cancer Center, 7Department of Gynecological Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, 8Department of Biostatistics, University of Texas MD Anderson Cancer Center, 9Department of Radiation Oncology, Stanford University Radiation therapy is a highly complex cancer treatment that requires multiple specialists to create a treatment plan and provide quality assurance (QA) prior to delivery to a patient. This protocol describes the use of a fully automated system, the Radiation Planning Assistant (RPA), to create high-quality radiation treatment plans.
Other articles by Angela Steinmann on PubMed
Whole Genomes Redefine the Mutational Landscape of Pancreatic Cancer Nature. | Pubmed ID: 25719666 Pancreatic cancer remains one of the most lethal of malignancies and a major health burden. We performed whole-genome sequencing and copy number variation (CNV) analysis of 100 pancreatic ductal adenocarcinomas (PDACs). Chromosomal rearrangements leading to gene disruption were prevalent, affecting genes known to be important in pancreatic cancer (TP53, SMAD4, CDKN2A, ARID1A and ROBO2) and new candidate drivers of pancreatic carcinogenesis (KDM6A and PREX2). Patterns of structural variation (variation in chromosomal structure) classified PDACs into 4 subtypes with potential clinical utility: the subtypes were termed stable, locally rearranged, scattered and unstable. A significant proportion harboured focal amplifications, many of which contained druggable oncogenes (ERBB2, MET, FGFR1, CDK6, PIK3R3 and PIK3CA), but at low individual patient prevalence. Genomic instability co-segregated with inactivation of DNA maintenance genes (BRCA1, BRCA2 or PALB2) and a mutational signature of DNA damage repair deficiency. Of 8 patients who received platinum therapy, 4 of 5 individuals with these measures of defective DNA maintenance responded.